SCHEMBL8537140

SCHEMBL8537140

Cc1cc(C=C2SCN(C)C2=O)cc(C)c1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
POLB P06746 1/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
KMT2A Q03164 1/20 0.50
CYP2C9 P11712 2/20 0.47
EEF2K O00418 1/20 0.45
SRC P12931 1/20 0.45
NAT1 P18440 4/20 0.40
AKR1B1 P15121 1/20 0.39
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2B6 P20813 1/20 0.37
SIRT1 Q96EB6 1/20 0.36
PTGS1 P23219 5/20 0.36
PTGS2 P35354 5/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8537136 1.00 MEN1 (0.50) MEN1NPC1ALDH1A1LMNAPOLB
SCHEMBL8991978 0.88 PTGS2 (0.48) MEN1NPC1ALDH1A1LMNAPOLB
SCHEMBL8893231 0.88 PTGS2 (0.48) MEN1NPC1ALDH1A1LMNAPOLB
SCHEMBL8957287 0.82 CYP1A2 (0.50) MEN1NPC1ALDH1A1LMNAPOLB
SCHEMBL8532777 0.81 PTGS2 (0.56) MEN1ALDH1A1GAAKMT2ACYP2C9
SCHEMBL8537121 0.81 CYP1A2 (0.51) NAT1CYP1A2CYP3A4CYP2B6PTGS1
SCHEMBL8991956 0.81 IGF1R (0.56) MEN1ALDH1A1LMNAPOLBGAA
SCHEMBL8537123 0.81 CYP1A2 (0.51) NAT1CYP1A2CYP3A4CYP2B6PTGS1
SCHEMBL8532780 0.81 PTGS2 (0.56) MEN1ALDH1A1GAAKMT2ACYP2C9
SCHEMBL8991957 0.81 IGF1R (0.56) MEN1ALDH1A1LMNAPOLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0434394-B1 Compounds for treating inflammatory bowel disease LILLY CO ELI (US) 1998-08-05 EP disclosed
US-5731336-A USING ARYL-SUBSTITUTED RHODAMINES ELI LILLY AND COMPANY (US) 1998-03-24 US disclosed
US-5691367-A ANTIINFLAMMATORY AGENTS OR ANTIARTHRITIC AGENTS ELI LILLY AND COMPANY (US) 1997-11-25 US disclosed
EP-0722729-A2 Aryl-substituted rhodanines for treating multiple sclerosis ELI LILLY AND COMPANY (US) 1996-07-24 EP disclosed
EP-0391644-B1 Aryl-substituted rhodanine derivatives LILLY CO ELI (US) 1996-06-19 EP disclosed
US-5356917-A Antiischemic, antiinflammatory, antiarthritic agents, treat-ment of dystrophic mammals ELI LILLY AND COMPANY (US) 1994-10-18 US disclosed
US-5216002-A Using benzyl substituted rhodanine derivatives as pure enantiomeric form ELI LILLY AND COMPANY (US) 1993-06-01 US disclosed
US-5158966-A Aryl-substituted rhodanine derivatives THE UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-10-27 US disclosed
EP-0500337-A1 Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes UNIVERSITY OF COLORADO FOUNDATION, INC. (US) 1992-08-26 EP disclosed
EP-0434394-A2 Compounds for treating inflammatory bowel disease ELI LILLY AND COMPANY (US) 1991-06-26 EP disclosed
EP-0391644-A2 Aryl-substituted rhodanine derivatives ELI LILLY AND COMPANY (US) 1990-10-10 EP disclosed